Finance
European pharma shares drop after Trump threatens more tariffs
Published by Global Banking & Finance Review®
Posted on September 26, 2025
1 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on September 26, 2025
1 min readLast updated: January 21, 2026
European pharma stocks fell after Trump announced new tariffs on branded drugs, affecting major companies like Novo Nordisk and Astrazeneca.
LONDON (Reuters) -Shares in Europe's biggest pharma companies fell in early trading on Friday, after U.S. President Donald Trump unveiled a new round of punishing tariffs, including 100% duties on branded drugs.
The announcements, made on Truth Social, did not include details about whether the new levies would apply on top of national tariffs or whether economies with trade deals such as the European Union and Japan would be exempted. Tokyo said it was still analyzing the potential impact of the new measures.
Shares in Novo Nordisk, Roche, Novartis and Astrazeneca were down betweeen 1.8% and 2% on the Tradegate platform.
(Reporting by Amanda Cooper; Editing by Anna Pruchnicka)
Shares in Europe's biggest pharma companies fell after U.S. President Donald Trump announced a new round of tariffs, including 100% duties on certain products.
Shares in Novo Nordisk, Roche, Novartis, and Astrazeneca were down between 1.8% and 2% on the Tradegate platform.
The announcements regarding the new tariffs were made on Truth Social.
The announcements did not clarify whether the new levies would apply on top of national tariffs or affect economies with trade deals like the European Union.
Explore more articles in the Finance category
